A group of researchers and investigators found that fisetin has inhibitory effect on different cancer stages (adhesion, migration, and invasion) of human lung adenocarcinoma A549 cells through multiple pathways such as down‐regulation of levels of matrix metalloproteinase‐2 (MMP‐2), urokinase‐type plasminogen activator (uPA), and suppression of phosphorylation of extracellular signal‐regulated kinases 1 and 2 (ERK1/2) at both the protein and mRNA levels. Here, PLAU is linked to lung adenocarcinoma.